down arrow

Agilent Technologies, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00846U1016
USD
148.32
-0.94 (-0.63%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

144.50149.29

52 Week

96.43160.27
Valuation
Technical
Day's Volume

CASH

597.34 k

Shareholding (Jul 2025)

FII

29.94%

Held by 462 FIIs

DII

29.67%

Held by 70 DIIs

Promoter

0.12%

How big is Agilent Technologies, Inc.?

22-Jun-2025

As of Jun 18, Agilent Technologies, Inc. has a market capitalization of $32.98 billion, with net sales of $6.63 billion and net profit of $1.17 billion over the latest four quarters.

As of Jun 18, Agilent Technologies, Inc. has a market capitalization of 32,977.07 million, categorizing it as a Large Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 6,628.00 million, while the sum of Net Profit for the same period is 1,166.00 million.<BR><BR>As of Oct'24, the reporting period shows Shareholder's Funds at 5,898.00 million and Total Assets at 11,931.00 million.

Read More

What does Agilent Technologies, Inc. do?

22-Jun-2025

Agilent Technologies, Inc. offers application-focused solutions for laboratory workflows in the Pharmaceuticals & Biotechnology industry, with recent net sales of $1.668 billion and a market cap of approximately $32.98 billion. Key financial metrics include a P/E ratio of 25.00 and a dividend yield of 64.19%.

Overview:<BR>Agilent Technologies, Inc. provides application-focused solutions, including instruments, software, services, and consumables for laboratory workflows, operating within the Pharmaceuticals & Biotechnology industry and classified as a Large Cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1,668 Million (Quarterly Results - Apr 2025) <BR>Most recent Net Profit: 215 Million (Quarterly Results - Apr 2025) <BR>Market cap: USD 32,977.07 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 25.00 <BR>Dividend Yield: 64.19% <BR>Debt Equity: 0.33 <BR>Return on Equity: 21.31% <BR>Price to Book: 5.37 <BR><BR>Contact Details:<BR>Address: 5301 Stevens Creek Blvd, SANTA CLARA CA: 95051-7201 <BR>Tel: 1 408 3458886 <BR>Fax: 1 408 3458474 <BR>Website: https://www.agilent.com/

Read More

Who are in the management team of Agilent Technologies, Inc.?

22-Jun-2025

As of March 2022, Agilent Technologies, Inc.'s management team includes Non-Executive Independent Chairman Boon Hwee Koh, President and CEO Michael McMullen, and Independent Directors Mala Anand, Hans Bishop, Paul Clark, and Heidi Kunz. They oversee the company's strategic direction and governance.

As of March 2022, the management team of Agilent Technologies, Inc. includes the following individuals:<BR><BR>- Mr. Boon Hwee Koh, who serves as the Non-Executive Independent Chairman of the Board.<BR>- Mr. Michael McMullen, who is the President, Chief Executive Officer, and a Director.<BR>- Ms. Mala Anand, who is an Independent Director.<BR>- Mr. Hans Bishop, who is also an Independent Director.<BR>- Mr. Paul Clark, who serves as an Independent Director.<BR>- Ms. Heidi Kunz, who is an Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and governance.

Read More

Is Agilent Technologies, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Agilent Technologies, Inc. shows a mildly bullish trend supported by positive MACD signals and strong recent performance compared to the S&P 500, despite lagging in longer-term returns.

As of 3 October 2025, the technical trend for Agilent Technologies, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, supporting a positive outlook. Additionally, the daily moving averages are bullish, while the Bollinger Bands indicate a mildly bullish stance on the weekly and a bullish stance on the monthly. The KST shows a bullish signal weekly but bearish monthly, and the Dow Theory indicates a mildly bullish trend on a monthly basis.<BR><BR>In terms of performance, Agilent's returns over the past week and month are significantly higher than the S&P 500, with a 14.43% return over the past week compared to 1.09% for the index, and a 9.99% return over the past month versus 4.15%. However, the longer-term returns, particularly over the past year and three years, lag behind the S&P 500.<BR><BR>Overall, the current technical stance is mildly bullish, driven primarily by the positive signals from MACD and moving averages.

Read More

Is Agilent Technologies, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Agilent Technologies is fairly valued with a P/E ratio of 25, lagging behind the S&P 500 with a 3.27% return over the past year, but showing stronger short-term performance with an 11.99% return in the last month.

As of 17 October 2025, Agilent Technologies, Inc. has moved from a very expensive valuation to fair. The company is currently fairly valued based on its financial metrics, with a P/E ratio of 25, an EV to EBITDA of 18.73, and a Price to Book Value of 5.36. In comparison, peers such as Edwards Lifesciences Corp. have a higher P/E of 31.17, while DexCom, Inc. is even more expensive with a P/E of 53.65, indicating that Agilent is relatively more attractively priced within its industry.<BR><BR>Despite its fair valuation, Agilent's recent stock performance has lagged behind the S&P 500, returning only 3.27% over the past year compared to the S&P 500's 14.08%. However, it has shown stronger returns over shorter periods, with a 1-month return of 11.99% versus the S&P 500's 0.96%. Overall, Agilent's valuation appears reasonable given its competitive positioning and performance metrics.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROCE of 20.72%

 
2

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.90 times

 
3

Flat results in Jul 25

4

With ROCE of 19.48%, it has a fair valuation with a 4.29 Enterprise value to Capital Employed

5

High Institutional Holdings at 93.78%

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 36,325 Million (Mid Cap)

stock-summary
P/E

25.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

39.43%

stock-summary
Debt Equity

0.29

stock-summary
Return on Equity

20.80%

stock-summary
Price to Book

5.70

Revenue and Profits:
Net Sales:
1,738 Million
(Quarterly Results - Jul 2025)
Net Profit:
336 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.44%
0%
15.44%
6 Months
29.04%
0%
29.04%
1 Year
5.79%
0%
5.79%
2 Years
15.08%
0%
15.08%
3 Years
-4.72%
0%
-4.72%
4 Years
-0.68%
0%
-0.68%
5 Years
28.81%
0%
28.81%

Agilent Technologies, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Agilent Technologies Experiences Revision in Its Stock Evaluation Amid Competitive Market Dynamics

Agilent Technologies Experiences Revision in Its Stock Evaluation Amid Competitive Market Dynamics

Agilent Technologies, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 25 and a price-to-book value of 5.36. The company maintains a strong dividend yield of 64.35% and competitive returns on capital and equity. Its stock performance has been resilient, though it lags behind the S&P 500.

Read More

Is Agilent Technologies, Inc. overvalued or undervalued?

As of 17 October 2025, Agilent Technologies, Inc. has moved from a very expensive valuation to fair. The company is currently fairly valued based on its financial metrics, with a P/E ratio of 25, an EV to EBITDA of 18.73, and a Price to Book Value of 5.36. In comparison, peers such as Edwards Lifesciences Corp. have a higher P/E of 31.17, while DexCom, Inc. is even more expensive with a P/E of 53.65, indicating that Agilent is relatively more attractively priced within its industry. Despite its fair valuation, Agilent's recent stock performance has lagged behind the S&P 500, returning only 3.27% over the past year compared to the S&P 500's 14.08%. However, it has shown stronger returns over shorter periods, with a 1-month return of 11.99% versus the S&P 500's 0.96%. Overall, Agilent's valuation appears reasonable given its competitive positioning and performance metrics....

Read More
Agilent Technologies Experiences Valuation Adjustment Amid Strong Competitive Metrics

Agilent Technologies Experiences Valuation Adjustment Amid Strong Competitive Metrics

Agilent Technologies, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 25 and a Price to Book Value of 5.36. The company demonstrates strong operational performance with a notable dividend yield and competitive returns, positioning it favorably against peers in the Pharmaceuticals & Biotechnology sector.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
5.38%
EBIT Growth (5y)
11.71%
EBIT to Interest (avg)
16.82
Debt to EBITDA (avg)
0.90
Net Debt to Equity (avg)
0.33
Sales to Capital Employed (avg)
0.75
Tax Ratio
14.95%
Dividend Payout Ratio
21.31%
Pledged Shares
0
Institutional Holding
95.10%
ROCE (avg)
20.72%
ROE (avg)
22.25%
Valuation key factors
Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
5.36
EV to EBIT
21.99
EV to EBITDA
18.73
EV to Capital Employed
4.29
EV to Sales
5.27
PEG Ratio
NA
Dividend Yield
64.35%
ROCE (Latest)
19.48%
ROE (Latest)
21.31%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jul 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 154 Schemes (40.2%)

Foreign Institutions

Held by 462 Foreign Institutions (29.94%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jul'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jul 2025 is 4.20% vs -0.77% in Apr 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jul 2025 is 56.28% vs -32.39% in Apr 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jul'25",
        "Apr'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,738.00",
          "val2": "1,668.00",
          "chgp": "4.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "457.00",
          "val2": "427.00",
          "chgp": "7.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "28.00",
          "val2": "29.00",
          "chgp": "-3.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-19.00",
          "val2": "-74.00",
          "chgp": "74.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "336.00",
          "val2": "215.00",
          "chgp": "56.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "221.50%",
          "val2": "212.20%",
          "chgp": "0.93%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Oct'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Oct 2024 is -4.73% vs -0.22% in Oct 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Oct 2024 is 3.95% vs -1.12% in Oct 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Oct'24",
        "Oct'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6,510.00",
          "val2": "6,833.00",
          "chgp": "-4.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,850.00",
          "val2": "1,899.00",
          "chgp": "-2.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "96.00",
          "val2": "93.00",
          "chgp": "3.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-83.00",
          "val2": "-316.00",
          "chgp": "73.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,289.00",
          "val2": "1,240.00",
          "chgp": "3.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "244.70%",
          "val2": "238.30%",
          "chgp": "0.64%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jul'25 - QoQstock-summary
Jul'25
Apr'25
Change(%)
Net Sales
1,738.00
1,668.00
4.20%
Operating Profit (PBDIT) excl Other Income
457.00
427.00
7.03%
Interest
28.00
29.00
-3.45%
Exceptional Items
-19.00
-74.00
74.32%
Consolidate Net Profit
336.00
215.00
56.28%
Operating Profit Margin (Excl OI)
221.50%
212.20%
0.93%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jul 2025 is 4.20% vs -0.77% in Apr 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jul 2025 is 56.28% vs -32.39% in Apr 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Oct'24stock-summary
Oct'24
Oct'23
Change(%)
Net Sales
6,510.00
6,833.00
-4.73%
Operating Profit (PBDIT) excl Other Income
1,850.00
1,899.00
-2.58%
Interest
96.00
93.00
3.23%
Exceptional Items
-83.00
-316.00
73.73%
Consolidate Net Profit
1,289.00
1,240.00
3.95%
Operating Profit Margin (Excl OI)
244.70%
238.30%
0.64%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Oct 2024 is -4.73% vs -0.22% in Oct 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Oct 2024 is 3.95% vs -1.12% in Oct 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Agilent Technologies, Inc. stock-summary
stock-summary
Agilent Technologies, Inc.
Pharmaceuticals & Biotechnology
Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business. Its life sciences and applied markets business segment offers instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid solutions businesses. Its Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio.
Company Coordinates stock-summary
Company Details
5301 Stevens Creek Blvd , SANTA CLARA CA : 95051-7201
stock-summary
Tel: 1 408 3458886
stock-summary
https://www.agilent.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."